The North America Sexually Transmitted Diseases (STD) Testing Market would witness market growth of 4.3% CAGR during the forecast period (2021-2027).
The prevalence of sexually transmitted diseases has increased as a result of a surge in unprotected intercourse, which would fuel the need for sexually transmitted disease testing globally. Even if a person has no symptoms but has had unprotected sex, doctors will usually recommend STD testing. Viral load monitoring, genotyping, immunoassays, and molecular diagnostics are some of the STD diagnostics available in the market.
Simultaneous testing for many targets is one way to improve testing reliability. Compensating for genotype changes, mutations, and mismatches have boosted the probability of detection for infections such as HIV, syphilis, hepatitis C virus (HCV), and chlamydia, and can help to detect cases of co-infection in advance.
According to CDC, in 2019, 2.5 million cases of gonorrhoea, chlamydia, and syphilis, which are the three most common STDs, were reported in the US. Between 2015 and 2019, there was an almost 30% increase in these reportable STDs. Owing to this rising prevalence of STDs in the US and other developed nations and the growing initiatives to aware people regarding STDs, the demand for STD testing would increase in the coming years. For instance, programs initiated by CDC stated that innovative STD testing procedures are crucial for STD prevention. STD care is growing beyond the clinic environment, with new options for phone, video, and online health care appointments. Expanding these measures can assist authorities in reducing STDs and addressing previously unresolved health-care access issues.
The US market dominated the North America Sexually Transmitted Diseases (STD) Testing Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $25.63 billion by 2027. The Canada market is poised to grow at a CAGR of 6.6% during (2021 - 2027). Additionally, The Mexico market would display a CAGR of 5.7% during (2021 - 2027).
Based on Disease Type, the market is segmented into Chlamydia, Herpes simplex, Gonorrhea, Syphilis, Human papillomavirus (HPV), and Other Disease. Based on the Location of Testing, the market is segmented into Laboratory Testing and Point of care (POC) Testing. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Sexually Transmitted Diseases (STD) Testing Market is Estimated to reach $120 Billion by 2027, at a CAGR of 4.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., DiaSorin Molecular LLC, Danaher Corporation, Bio-Rad Laboratories, Inc., and OraSure Technologies, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Disease Type
- Chlamydia
- Herpes simplex
- Gonorrhea
- Syphilis
- Human papillomavirus (HPV)
- Other Disease
By Location of Testing
- Laboratory Testing
- Point of care (POC) Testing
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- BioMérieux S.A.
- Abbott Laboratories
- Becton, Dickinson and Company
- Hologic, Inc.
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- DiaSorin Molecular LLC
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- OraSure Technologies, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Sexually Transmitted Diseases (STD) Testing Market, by Disease Type
1.4.2 North America Sexually Transmitted Diseases (STD) Testing Market, by Location of Testing
1.4.3 North America Sexually Transmitted Diseases (STD) Testing Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Product Launches and Product Expansions: 2019, Oct – 2021, Dec) Leading Players
Chapter 4. North America Sexually Transmitted Diseases (STD) Testing Market by Disease Type
4.1 North America Chlamydia Market by Country
4.2 North America Herpes simplex virus Market by Country
4.3 North America Gonorrhea Market by Country
4.4 North America Syphilis Market by Country
4.5 North America Human papillomavirus (HPV) Market by Country
4.6 North America Other Disease Market by Country
Chapter 5. North America Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
5.1 North America Laboratory Testing Market by Country
5.2 North America Point of care (POC) Testing Market by Country
Chapter 6. North America Sexually Transmitted Diseases (STD) Testing Market by Country
6.1 US Sexually Transmitted Diseases (STD) Testing Market
6.1.1 US Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.1.2 US Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.2 Canada Sexually Transmitted Diseases (STD) Testing Market
6.2.1 Canada Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.2.2 Canada Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.3 Mexico Sexually Transmitted Diseases (STD) Testing Market
6.3.1 Mexico Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.3.2 Mexico Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.4 Rest of North America Sexually Transmitted Diseases (STD) Testing Market
6.4.1 Rest of North America Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.4.2 Rest of North America Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
Chapter 7. Company Profiles
7.1 BioMérieux S.A.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Research & Development Expenses
7.2 Abbott Laboratories
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Approvals and Trials:
7.3 Becton, Dickinson and Company
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Product Launches and Product Expansions:
7.4 Hologic, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.4.5.2 Product Launches and Product Expansions:
7.4.5.3 Acquisition and Mergers:
7.5 Thermo Fisher Scientific, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.5.6 SWOT Analysis
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Product Launches and Product Expansions:
7.7 DiaSorin Molecular LLC
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Danaher Corporation
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Bio-Rad laboratories, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Acquisition and Mergers:
7.10. OraSure Technologies, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional & Segmental Analysis
7.10.4 Research & Development Expenses
7.10.5 Recent strategies and developments:
7.10.5.1 Product Launches and Product Expansions:
7.10.5.2 Acquisition and Mergers:
TABLE 1 North America Sexually Transmitted Diseases (STD) Testing Market, 2017 - 2020, USD Million
TABLE 2 North America Sexually Transmitted Diseases (STD) Testing Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Sexually Transmitted Diseases (STD) Testing Market
TABLE 4 Product Launches And Product Expansions– Sexually Transmitted Diseases (STD) Testing Market
TABLE 5 Acquisition and Mergers– Sexually Transmitted Diseases (STD) Testing Market
TABLE 6 approvals and trials– Sexually Transmitted Diseases (STD) Testing Market
TABLE 7 North America Sexually Transmitted Diseases (STD) Testing Market by Disease Type, 2017 - 2020, USD Million
TABLE 8 North America Sexually Transmitted Diseases (STD) Testing Market by Disease Type, 2021 - 2027, USD Million
TABLE 9 North America Chlamydia Market by Country, 2017 - 2020, USD Million
TABLE 10 North America Chlamydia Market by Country, 2021 - 2027, USD Million
TABLE 11 North America Herpes simplex virus Market by Country, 2017 - 2020, USD Million
TABLE 12 North America Herpes simplex virus Market by Country, 2021 - 2027, USD Million
TABLE 13 North America Gonorrhea Market by Country, 2017 - 2020, USD Million
TABLE 14 North America Gonorrhea Market by Country, 2021 - 2027, USD Million
TABLE 15 North America Syphilis Market by Country, 2017 - 2020, USD Million
TABLE 16 North America Syphilis Market by Country, 2021 - 2027, USD Million
TABLE 17 North America Human papillomavirus (HPV) Market by Country, 2017 - 2020, USD Million
TABLE 18 North America Human papillomavirus (HPV) Market by Country, 2021 - 2027, USD Million
TABLE 19 North America Other Disease Market by Country, 2017 - 2020, USD Million
TABLE 20 North America Other Disease Market by Country, 2021 - 2027, USD Million
TABLE 21 North America Sexually Transmitted Diseases (STD) Testing Market by Location of Testing, 2017 - 2020, USD Million
TABLE 22 North America Sexually Transmitted Diseases (STD) Testing Market by Location of Testing, 2021 - 2027, USD Million
TABLE 23 North America Laboratory Testing Market by Country, 2017 - 2020, USD Million
TABLE 24 North America Laboratory Testing Market by Country, 2021 - 2027, USD Million
TABLE 25 North America Point of care (POC) Testing Market by Country, 2017 - 2020, USD Million
TABLE 26 North America Point of care (POC) Testing Market by Country, 2021 - 2027, USD Million
TABLE 27 North America Sexually Transmitted Diseases (STD) Testing Market by Country, 2017 - 2020, USD Million
TABLE 28 North America Sexually Transmitted Diseases (STD) Testing Market by Country, 2021 - 2027, USD Million
TABLE 29 US Sexually Transmitted Diseases (STD) Testing Market, 2017 - 2020, USD Million
TABLE 30 US Sexually Transmitted Diseases (STD) Testing Market, 2021 - 2027, USD Million
TABLE 31 US Sexually Transmitted Diseases (STD) Testing Market by Disease Type, 2017 - 2020, USD Million
TABLE 32 US Sexually Transmitted Diseases (STD) Testing Market by Disease Type, 2021 - 2027, USD Million
TABLE 33 US Sexually Transmitted Diseases (STD) Testing Market by Location of Testing, 2017 - 2020, USD Million
TABLE 34 US Sexually Transmitted Diseases (STD) Testing Market by Location of Testing, 2021 - 2027, USD Million
TABLE 35 Canada Sexually Transmitted Diseases (STD) Testing Market, 2017 - 2020, USD Million
TABLE 36 Canada Sexually Transmitted Diseases (STD) Testing Market, 2021 - 2027, USD Million
TABLE 37 Canada Sexually Transmitted Diseases (STD) Testing Market by Disease Type, 2017 - 2020, USD Million
TABLE 38 Canada Sexually Transmitted Diseases (STD) Testing Market by Disease Type, 2021 - 2027, USD Million
TABLE 39 Canada Sexually Transmitted Diseases (STD) Testing Market by Location of Testing, 2017 - 2020, USD Million
TABLE 40 Canada Sexually Transmitted Diseases (STD) Testing Market by Location of Testing, 2021 - 2027, USD Million
TABLE 41 Mexico Sexually Transmitted Diseases (STD) Testing Market, 2017 - 2020, USD Million
TABLE 42 Mexico Sexually Transmitted Diseases (STD) Testing Market, 2021 - 2027, USD Million
TABLE 43 Mexico Sexually Transmitted Diseases (STD) Testing Market by Disease Type, 2017 - 2020, USD Million
TABLE 44 Mexico Sexually Transmitted Diseases (STD) Testing Market by Disease Type, 2021 - 2027, USD Million
TABLE 45 Mexico Sexually Transmitted Diseases (STD) Testing Market by Location of Testing, 2017 - 2020, USD Million
TABLE 46 Mexico Sexually Transmitted Diseases (STD) Testing Market by Location of Testing, 2021 - 2027, USD Million
TABLE 47 Rest of North America Sexually Transmitted Diseases (STD) Testing Market, 2017 - 2020, USD Million
TABLE 48 Rest of North America Sexually Transmitted Diseases (STD) Testing Market, 2021 - 2027, USD Million
TABLE 49 Rest of North America Sexually Transmitted Diseases (STD) Testing Market by Disease Type, 2017 - 2020, USD Million
TABLE 50 Rest of North America Sexually Transmitted Diseases (STD) Testing Market by Disease Type, 2021 - 2027, USD Million
TABLE 51 Rest of North America Sexually Transmitted Diseases (STD) Testing Market by Location of Testing, 2017 - 2020, USD Million
TABLE 52 Rest of North America Sexually Transmitted Diseases (STD) Testing Market by Location of Testing, 2021 - 2027, USD Million
TABLE 53 Key information – BioMérieux S.A.
TABLE 54 Key Information – Abbott Laboratories
TABLE 55 Key information – Becton, Dickinson and Company
TABLE 56 Key information – Hologic, Inc.
TABLE 57 Key Information – Thermo Fisher Scientific, Inc.
TABLE 58 key information – F. Hoffmann-La Roche Ltd.
TABLE 59 Key information – DiaSorin Molecular LLC
TABLE 60 Key Information – Danaher Corporation
TABLE 61 Key Information – Bio-Rad Laboratories, Inc.
TABLE 62 Key information – OraSure Technologies, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 1 KBV Cardinal Matrix
FIG 2 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 3 Key Strategic Move: (Product Launches and Product Expansions : 2019, Oct – 2021, dec) Leading Players
FIG 4 Recent strategies and developments: Hologic, Inc.
FIG 5 Swot analysis: thermo fisher scientific, inc.
FIG 6 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 7 Recent strategies and developments: OraSure Technologies, Inc.